Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

Table 4 Multivariable logistic regression analyses: CYP19A variant and AIAA

Risk factors	AOR (95% C.I.)	P-value	AOR (95% C.I.)	P-value
Genotype	CYP19A7r		CYP19A8r
Non-carrier (Reference)	1	-	1	-
Carrier	1.70 (1.06 to 2.73)	0.028	0.41 (0.21 to 0.79)	0.008
Time since LMP
>10 years (Reference)	1	-	1	-
5 to 10 years	2.15 (1.27 to 3.67)	0.005	2.14 (1.26 to 3.66)	0.005
<5 years	3.28 (1.71 to 6.29)	<0.001	3.31 (1.72 to 6.39)	<0.001
Type of menopause
Natural (Reference)	1	-	1	-
Induced	0.82 (0.55 to 1.21)	0.32	0.81 (0.55 to 1.20)	0.30
Years since start of AI
<1 year (Reference)	1	-	1	-
1 to 3 years	1.45 (0.82 to 2.58)	0.20	1.48 (0.83 to 2.62)	0.18
>3 years	0.78 (0.45 to 1.33)	0.36	0.77 (0.45 to 1.33)	0.35
Education
High school	1	-	1	-
College and graduate school	1.02 (0.76 to 1.38)	0.87	1.05 (0.78 to 1.43)	0.93
Chemotherapy
None (Reference)	1	-	1	-
Chemotherapy but no taxane	0.97 (0.54 to 1.74)	0.92	1.02 (0.57 to 1.83)	0.85
Chemotherapy included taxane	1.52 (0.89 to 2.61)	0.12	1.61 (0.93 to 2.78)	0.09

Abbreviations: AOR, adjusted odds ratio; 95% CI, 95% confidence interval; LMP, last menstrual period.

ISSN: 1465-542X